ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Journal of Clinical Oncology · 10.05.2023 · 41 (14) · 2628-2637
DOI: 10.1200/jco.22.01693 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2023. Verfasst von Eric Van Cutsem und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Leuven and KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAF V600E -mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 ). ANCHOR CRC aimed to evaluate efficacy, safety, and quality of life with first-line encorafenib + binimetinib + cetuximab in BRAF V600E -mutated mCRC. METHODS In this multicenter, open-label, single-arm study, patients with BRAF V600E -mutated mCRC received oral encorafenib 300 mg once daily and binimetinib 45 mg twice daily in 28-day cycles, plus intravenous cetuximab 400 mg/m 2 once on day 1 of cycle 1, then 250 mg/m 2 once weekly for the first seven cycles, and 500 mg/m 2 once on Days 1 and 15 from cycle 8 onward. The primary end point was locally assessed confirmed objective response rate (cORR), and secondary end points included centrally assessed cORR, progression-free survival, overall survival (OS), quality of life, and safety and tolerability. RESULTS Among 95 patients, the locally assessed cORR was 47.4% (95% CI, 37.0 to 57.9) with all partial responses. Since the lower limit of the 95% CI exceeded 30%, the primary end point was met. With a median follow-up duration of 20.1 months, the median progression-free survival on the basis of local assessments was 5.8 months and the median OS was 18.3 months. Treatment was well tolerated, with no unexpected toxicities. Using Patient Global Impression of Changes, substantial improvement in symptoms was consistently reported in ≥ 30% of patients from cycle 3 to cycle 10. CONCLUSION The ANCHOR CRC study showed that the scientifically driven combination of encorafenib + binimetinib + cetuximab was active in the first-line setting of BRAF V600E -mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Leuven and KU Leuven, Leuven, Belgium.
- Department of Hepatogastroenterology and Gastrointestinal Oncology, University Paris-cité (Paris Descartes), SIRIC CARPEM, Georges Pompidou European Hospital, AP-HP, Paris, France.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- West Cancer Center and Research Institute, Germantown, TN.
- Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
ORCID-Profile: Eric Van Cutsem, Julien Taieb, Rona Yaeger, Takayuki Yoshino, Axel Grothey, Evaristo Maiello, Jeroen Dekervel, Paul Ross, Jose C Ruffinelli, Thierry André, Josep Tabernero
Förderung
- NCI NIH HHS
Zitieren
APA
Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., Graham, J., Kato, T., Ruffinelli, J. C., André, T., Carrière Roussel, E., Klauck, I., Groc, M., Vedovato, J. C., & Tabernero, J. (2023). ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology, 41(14), 2628-2637. https://doi.org/10.1200/jco.22.01693
Vancouver
Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, et al. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2023;41(14):2628-2637. doi:10.1200/jco.22.01693
BibTeX
@article{VanCutsem2023,
author = {Van Cutsem, Eric and Taieb, Julien and Yaeger, Rona and Yoshino, Takayuki and Grothey, Axel and Maiello, Evaristo and Elez, Elena and Dekervel, Jeroen and Ross, Paul and Ruiz-Casado, Ana and Graham, Janet and Kato, Takeshi and Ruffinelli, Jose C and André, Thierry and Carrière Roussel, Edith and Klauck, Isabelle and Groc, Mélanie and Vedovato, Jean-Claude and Tabernero, Josep},
title = {ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {14},
pages = {2628--2637},
doi = {10.1200/jco.22.01693}
}
EUVIMED